# Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL

> **NCT07724782** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 33 (estimated)

## Conditions studied

- PTCL-NOS

## Interventions

- **DRUG:** Zeprumetostat( an EZH2 inhibitor) + X

## Key facts

- **NCT ID:** NCT07724782
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2030-07-30
- **Final completion:** 2031-07-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724782, "Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07724782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*